Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: [1]
In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3] They are used to treat both hepatitis B, [4] hepatitis C [1] and multiple sclerosis. [2]
Pegylated interferon is contraindicated in patients with hyperbilirubinaemia.[ citation needed]
References
- ^
a
b editor, Emilio Jirillo (2008).
Hepatitis C virus disease : immunobiology and clinical applications ([Online-Ausg.] ed.). New York: Springer. p. 237.
ISBN
978-0-387-71375-5.
{{ cite book}}:|last=has generic name ( help) - ^ a b Kieseier BC, Calabresi PA.; Calabresi (2012). "PEGylation of Interferon-β-1a: A Promising Strategy in Multiple Sclerosis". CNS Drugs. 26 (3): 205–14. doi: 10.2165/11596970-000000000-00000. PMID 22201341. S2CID 34290702. Archived from the original on 2013-01-01.
- ^ Martin P (February 15, 2001). "Hepatology Focus: Update on Hepatitis C Treatment: Pegylated Interferon". medscape.
- ^ Dancygier H, Allescher HD (2010). Clinical Hepatology. [S.l.]: Springer Berlin Heidelberg. p. 765. ISBN 978-3-642-04509-7.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: [1]
In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3] They are used to treat both hepatitis B, [4] hepatitis C [1] and multiple sclerosis. [2]
Pegylated interferon is contraindicated in patients with hyperbilirubinaemia.[ citation needed]
References
- ^
a
b editor, Emilio Jirillo (2008).
Hepatitis C virus disease : immunobiology and clinical applications ([Online-Ausg.] ed.). New York: Springer. p. 237.
ISBN
978-0-387-71375-5.
{{ cite book}}:|last=has generic name ( help) - ^ a b Kieseier BC, Calabresi PA.; Calabresi (2012). "PEGylation of Interferon-β-1a: A Promising Strategy in Multiple Sclerosis". CNS Drugs. 26 (3): 205–14. doi: 10.2165/11596970-000000000-00000. PMID 22201341. S2CID 34290702. Archived from the original on 2013-01-01.
- ^ Martin P (February 15, 2001). "Hepatology Focus: Update on Hepatitis C Treatment: Pegylated Interferon". medscape.
- ^ Dancygier H, Allescher HD (2010). Clinical Hepatology. [S.l.]: Springer Berlin Heidelberg. p. 765. ISBN 978-3-642-04509-7.
|
| This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
|
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |